Bristol-Myers Squibb Company (BMY) is currently trading at $57.13, reflecting a positive price change of 23 cents (0.404%) from the previous close of $56.9. The trading volume stands at $3.48 million, showing a 25.43% increase relative to the average volume.
BMY's latest quarterly earnings report, released on Wednesday, April 29th, revealed a consensus estimate EPS of 1.44.
The company offers a forward dividend yield of 4.41%, with a dividend per share MRQ of 63 cents and a year-over-year increase of 2.8926 cents. The trailing twelve months dividend per share is $2.5.
BMY's financial health is evident in its free cash flow of $757 million, while prudent debt management is highlighted by a debt repayment of $179 million. The company reported a net decrease in cash of $635 million, with an ending cash balance of $9.58 billion.
The income statement showcases BMY's robust performance with revenues amounting to $11.49 billion and a gross profit of $8 billion. The company reported a net income of $2.68 billion, translating to an EPS of $1.31.
Key ratios for BMY include a net profit margin of 23.31%, return on equity of 13.34%, and a price-to-earnings ratio of 11.57.
The balance sheet indicates a strong financial position with total assets of $86.48 billion and total liabilities of $66.37 billion. The company holds $9.57 billion in cash and cash equivalents.
This financial report reflects Bristol-Myers Squibb Company's solid performance and financial stability in the current market landscape.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.